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Abstract
Aims/hypothesis Glomerular hyperfiltration is a well-
established phenomenon occurring early in some patients
with type 1 diabetes. However, there is no consistent
answer regarding whether hyperfiltration predicts later
development of nephropathy. We performed a systematic
review and meta-analysis of observational studies that
compared the risk of developing diabetic nephropathy in
patients with and without glomerular hyperfiltration and
also explored the impact of baseline GFR.
Methods A systematic review and meta-analysis was
carried out. Cohort studies in type 1 diabetic participants
were included if they contained data on the development of
incipient or overt nephropathy with baseline measurement
of GFR and presence or absence of hyperfiltration.
Results We included ten cohort studies following 780
patients. After a study median follow-up of 11.2 years,
130 patients had developed nephropathy. Using a random
effects model, the pooled odds of progression to a mini-
mum of microalbuminuria in patients with hyperfiltration
was 2.71 (95% CI 1.20–6.11) times that of patients with
normofiltration. There was moderate heterogeneity (hetero-
geneity test p=0.05, measure of degree of inconsistency=
48%) and some evidence of funnel plot asymmetry, pos-
sibly due to publication bias. The pooled weighted mean
difference in baseline GFR was 13.8 ml min−1 1.73 m−2
(95% CI 5.0–22.7) greater in the group progressing to
nephropathy than in those not progressing (heterogeneity
test p<0.01).
Conclusions/interpretation In published studies, individu-
als with glomerular hyperfiltration were at increased risk of
progression to diabetic nephropathy using study level data.
Further larger studies are required to explore this relation-
ship and the role of potential confounding variables.
Keywords Diabetic nephropathy . Glomerular
hyperfiltration .Meta-analysis . Observational studies .
Progression
Abbreviation
I2 Measure of degree of inconsistency
Introduction
Glomerular hyperfiltration is a phenomenon found early in
the clinical course of diabetes and its presence has been
suggested to be a risk factor for future diabetic nephropathy
[1]. In animal studies, when new-onset diabetes is induced
by streptozotocin in Munich–Wistar rats, single nephron
GFR is increased in animals with moderate hyperglycaemia
[2, 3]. Clinically, GFR is increased in newly diagnosed type
1 diabetic patients compared with non diabetic patients of a
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similar age. Moreover, in approximately 25–40% of patients
with type 1 diabetes, GFR can increase to as much as 160–
180 ml/min. This is assumed to be related to metabolic
control, as reduction of blood glucose with insulin therapy
returns GFR to near normal levels [4, 5].
Glomerular hyperfiltration has been attributed to abnor-
malities in the glomerulus and glomerular vessels. GFR is
determined by renal plasma flow, the transmembrane
hydraulic pressure gradients and the ultrafiltration coefficient.
Renal plasma flow is reliant on changes between afferent and
efferent renal arteriolar resistance; the transmembrane hy-
draulic pressure gradient is the difference between the mean
pressure in the glomerular capillary and the proximal tubule;
and the ultrafiltration coefficient is related to the filtration
surface area and its permeability. All of these factors are
altered in patients with diabetes, although the timing of these
dynamic changes is still unclear [6–8].
Uncertainty remains regarding whether glomerular hae-
modynamic changes similar to those found in patients with
type 1 diabetes mellitus are also present in type 2 diabetes. In
studies in Pima Indians, GFR was found to be 15% higher
in recent-onset type 2 diabetic patients [9]. However, these
changes were no longer significant when corrected for body
surface area and were not confirmed by another smaller study
[10]. Additionally, in longitudinal studies the GFR was found
to be elevated at the onset of type 2 diabetes and remained so
until the onset of overt nephropathy [11]. Similar changes
have been demonstrated in white patients, with hyperfiltration
present in 16% of 110 previously untreated type 2 diabetic
patients [12]. Further cross-sectional studies measuring GFR
isotopically have also demonstrated hyperfiltration in various
racial groups [13-17].
Renal haemodynamics are likely to play a crucial role in
the progression of diabetic nephropathy and may even
contribute to its initiation. The available evidence on hyper-
filtration risk in human studies is, however, conflicting,
while the power of many studies to determine whether
hyperfiltration predicts later development of nephropathy is
limited. Therefore we performed a systematic review and
meta-analysis of studies that compared the risk of develop-
ing diabetic nephropathy in type 1 diabetic patients with
and without glomerular hyperfiltration at baseline; we also
assessed the effect on progression to nephropathy of
baseline GFR measurements as a more continuous variable.
Methods
Literature search MEDLINE and EMBASE were searched
from the start date of each source to March 2008 using the
search strategy: (Diabetes mellitus, type 1 or Diabetes
complications or Diabetes or Diabetes mellitus, type 2 or
Diabetes mellitus) and (Nephropathy or Incipient or
Diabetic nephropathies or Overt or Proteinuria or Albu-
minuria or Microalbuminuria) and (Glomerular filtration
rate or Hyperfiltration) and (Cohort studies or Case–control
studies). There were no limits on language. Abstracts were
screened independently by two investigators (G. M. Magee
and D. G. Fogarty) and full text articles were retrieved if
relevant. Bibliographies of retrieved papers were also
searched.
Inclusion and exclusion criteria Studies with type 1
diabetes were included if they contained data on the
development of incipient or overt nephropathy over time.
Development of diabetic nephropathy was defined by the
progression from normoalbuminuria to microalbuminuria or
macroalbuminuria during the duration of follow-up. Albu-
min excretion rates categorising incipient or overt nephrop-
athy were taken as stated by the individual papers, as they
were dependent on the assay used by each laboratory. Data
on patients who developed transient or intermittent micro-
albuminuria, as defined in the studies, were not included in
the analysis.
Studies also had to include baseline mean GFR measure-
ments or a baseline determination of the presence or
absence of hyperfiltration. The level of hyperfiltration was
usually defined by the studies depending upon the method
of GFR determination employed. This information enabled
us to identify a group of patients who were hyperfiltering at
the beginning of the studies and a group with normal GFR,
and extract the number of patients in each group who
subsequently developed diabetic nephropathy. To enable
GFR to be assessed as a continuous measure, the baseline
mean (± SD) GFR of those who later developed and did not
develop nephropathy was also extracted from the papers
where possible. All relevant papers were included and
attempts were made to contact original authors if data were
missing. Any disagreements in numbers were resolved by
consensus between G. M. Magee, C. R. Cardwell and D. G.
Fogarty. Studies or cases in studies were excluded if they
were not normoalbuminuric at baseline or if follow-up data
were missing.
Data extraction Eligible studies were assessed independent-
ly by two reviewers (G. M. Magee and C. R. Cardwell).
Study information on country, year of publication, duration
of follow-up, duration of diabetes at baseline, age of
diagnosis of diabetes, a measure of glycaemic control and
blood pressure was also retrieved. Not all studies defined a
level for hyperfiltration. In these cases, a level greater or
equal to 140 ml min−1 1.73 m−2 was used arbitrarily.
Statistical analysis ORs and their SEs were calculated for
the association between progression to incipient or overt
nephropathy and the baseline presence of hyperfiltration for
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each study. A combined pooled OR was then derived using
a random effects model, as we had anticipated some
between-study heterogeneity, given that observational stud-
ies were being reviewed. Mean baseline differences in GFR
between patients progressing to nephropathy and those
without nephropathy during follow-up were also calculated,
enabling a pooled weighted mean difference in GFR to be
formulated, again using a random effects model to allow for
between-study heterogeneity. Tests for heterogeneity be-
tween studies were conducted and the measure of degree of
inconsistency (I2) statistic was used to quantify the degree
of this heterogeneity [18]. This value describes the total
variation across the studies that is due to heterogeneity
rather than chance (with I2 values of 25%, 50% and 75%
being tentatively considered low, moderate and high
heterogeneity respectively).
Publication bias was analysed by examining a funnel
plot looking for asymmetry in plotted ORs against the SE
of the logarithm of the ORs (a measure of study size).
Begg’s and Egger’s tests for publication bias were also
applied [19, 20]. All statistical analyses were performed
using Stata 9.0 software (Stata, College Station, TX, USA).
Results
A total of 23 papers was retrieved for further evaluation,
from which three cohort studies were selected for the meta-
analysis. A further eight studies with the desired infor-
mation were retrieved from studying bibliographies. We
excluded 77 abstracts, five due to the presence of baseline
microalbuminuria or proteinuria, 14 due to study design,
four because studies contained participants without diabetes
and 15 because other causes of nephropathy were included.
Ten excluded studies described the use of novel markers
and 29 others were excluded as they did not have any
patients with GFR in the hyperfiltration range at baseline or
because data were presented in such a way that the baseline
GFRs could not be derived. One initially included report
was subsequently removed from the analysis because it
comprised patients with type 2 diabetes only, and as such
was felt to be not comparable to the other studies [21]. In
the end, ten cohort studies from six countries following 780
patients were included in this meta-analysis [22–31]. The
publication years spanned three decades from 1984 to 2006
and all studies were of type 1 diabetic patients. The mean
age at diabetes diagnosis was 12.3 years. The definition of
hyperfiltration across the studies ranged from ≥125 to
≥140 ml min−1 1.73 m−2. Four studies did not define a level
of hyperfiltration and in these, this was arbitrarily taken as
≥140 ml min−1 1.73 m−2 (Table 1).
At the start of the studies, the mean duration of diabetes
was 8.1 years and the mean overall follow-up of the cohorts
was 11.2 years (Table 1). No studies had any participants
on anti-hypertensive medication at baseline. In the three
oldest studies HbA1c was not available as a measure of
glycaemic control, two other studies used HbA1 measure-
ments (Table 1). An estimate of HbA1c (%) was established
for these older studies using mean plasma glucose results
and the reverse of the formula for estimated average
glucose [32]: estimated average glucose mmol 1= Þ ¼ð
1:583 HbA1c  2:52 (Table 1). The mean HbA1c of
Table 1 Characteristics of ten studies included in the meta-analysis
First author
[reference no.]
Year Country Hyperfiltration
definition
(ml min−1
1.73 m−2)a
Patients
included
(n)
Mean age at
diagnosis
(years)
Mean
follow-up
(years)
Mean baseline
diabetes
duration (years)
Mean baseline HbA1c
(%)
Mean baseline blood
pressure (mmHg)
Progression No
progression
Progression No
progression
Mogensen [22] 1984 Denmark ND 24 12.3 10.4 12.6 6.9b 7.4b 135/89 124/80
Lervang [23] 1988 Denmark ND 29 18.9 18.5 3.4 9.3b 7.2b 118/76 119/76
Lervang [24] 1992 Denmark ND 34 7.0 12.0 7.0 10.8b 9.0 128/83 115/70
Chiarelli [25] 1995 Italy 140 c 46 6.2 10.0 9.7 12.2d 9.5d NA NA
Yip [26] 1996 England 135 45 21.5 9.5 8.0 NA NA NA NA
Caramori [27] 1999 Brazil 134 c 33 25.3 8.4 6.5 11.4d 9.9d NA NA
Dahlquist [28] 2001 Sweden 125 43 6.0 18.0 10.9 12.2 12.0 121/74 115/74
Amin [29] 2005 England 125 273 9.3 10.9 5.1 10.8 9.7 NA NA
Steinke [30] 2005 USA 130 107 8.7 5.0 8.0 9.2 8.4 114/64 114/64
Zerbini [31] 2006 Italy ND 146 7.3 9.5 9.5 9.8 9.0 119/74 118/74
Total 780
Mean 12. 3 11.2 8.1 10.5 9.6 123/77 118/73
aWhere not defined (ND), arbitrarily set at >140 ml min−1 1.73 m−2
b HbA1c estimated using reverse estimated average glucose formula (these values omitted when calculating mean)
c Single compartment GFR estimation technique
d HbA1 measurements (these values omitted when calculating mean)
NA, not available
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patients with progression to nephropathy was 10.5% com-
pared with 9.6% in those not progressing.
The association between hyperfiltration and progression
to diabetic nephropathy is shown in Fig. 1. Using the
random effects model, the pooled odds of progression to a
minimum of incipient nephropathy was 2.71 (95% CI 1.20–
6.11) times those in patients with normofiltration at base-
line, but there was evidence of heterogeneity (p=0.05, I2=
48%). In addition, the funnel plot shown in Fig. 2 suggests
some evidence of asymmetry, although formal tests were
not significant (Begg’s p=0.2, Egger’s p=0.1).
Of the ten studies included, nine compared the mean
difference in GFR in the groups with and without prog-
ression. One study could not be included for analysis on
this point, as the relevant data could not be extracted [26].
In the nine studies included, the combined mean baseline
GFR was 13.8 ml min−1 1.73 m−2 greater in the patient groups
progressing to nephropathy than in those not progressing.
However, there was marked heterogeneity (I2=77% [95%
CI 57–88%]) between studies, indicating that it may not be
appropriate to produce overall estimates (Fig. 3). The funnel
plot (not shown) suggested very little evidence of publica-
tion bias (Begg’s test p=0.92, Egger’s test p=0.99).
Analysis excluding the two studies that used an uncorrected
single compartment model for GFR calculation did not
considerably alter the overall OR or improve heterogeneity.
Discussion
This meta-analysis indicates that type 1 diabetic patients
with hyperfiltration are 2.7 times more likely to progress
to incipient nephropathy than those with normofiltration
and that patients who progressed had a higher baseline
GFR.
The strength of this analysis is that it is the first study
combining estimates from previous smaller observational
studies on the risk of progression in the presence of
hyperfiltration and thereby allowing more power to detect
any differences as significant. However, these findings
should be interpreted cautiously, as for both analyses there
was apparent heterogeneity. Furthermore, in the hyper-
filtration analysis, although not detected in formal tests, a
funnel plot supplied evidence of asymmetry, with small
published studies observing more marked increases in the
risk of progression to nephropathy after hyperfiltration.
This pattern is consistent with publication bias (resulting
from small studies observing no associations or inverse
associations not being published), which, if present, would
result in the combined OR overestimating the increased risk
of progression to nephropathy after hyperfiltration.
The association between progression and hyperfiltration
had an I2 value of 48%, indicating low to moderate
heterogeneity, but this was greater (I2=77%) when the
mean GFR between patients who progressed and those who
did not was compared. There are various explanations for
this marked heterogeneity, including differences in the year
[24]
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Fig. 2 Funnel plot of the association between hyperfiltration and
diabetic nephropathy. Dashed line, pooled estimate; dots, study as
denoted by reference number
Fig. 1 Forest plot of studies investigating the association between
hyperfiltration and progression Number of studies, n=10. aTest for
heterogeneity χ2=17.15, df=9.0, p=0.05; I2=48 (95% CI 0–75)%; test
for overall effect Z=2.39, p=0.02. DN, diabetic nephropathy; HF,
baseline hyperfiltration
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of study, glycaemic control, treatments and improvement in
screening for complications.
Various techniques were employed throughout the
studies to measure the GFR, with some of the studies using
a single compartment analysis. This has been shown to
overestimate GFR by as much as 25% to 30% in the upper
range of clearance values when compared with a two
compartment model [33]. The use of this model, if not
corrected, would tend to overestimate the numbers of
patients with hyperfiltration. When the studies not correct-
ing for this potential weakness were removed from our
analysis, heterogeneity did not improve and the combined
OR did not markedly change, falling to 2.32 (Fig. 3).
Hyperfiltration has been found to be more prevalent in
those with recent onset of diabetes and when glycaemic
control is poor [1, 4, 5]. It would therefore be essential to
compare duration of diabetes at entry into the study, as
patients with shorter disease duration are more likely to
have hyperfiltration. The mean duration of diabetes at entry
into the studies analysed was 8.1 years, but this ranged
from 3.4 to 12.6 years [22, 23]. Patients should therefore
have been on established glycaemic therapy even in the
studies with the shortest disease duration at baseline. Two
studies had calculated odds strongly against hyperfiltration
as a risk factor for progression [23, 24]. The first of these
had the shortest duration of diabetes, but participants were
diagnosed at an older mean age of 18.9 years and followed
up for the longest period of time (18.5 years). It is therefore
surprising that this group, with a 69% prevalence of
hyperfiltration, had the lowest risk of progressing to
nephropathy. It is generally recognised that younger age
of diabetes onset also leads to a younger age of progression
[34]; however, these older patients were diagnosed years
after exposure to pubertal hormonal changes, which are
thought to increase hyperfiltration, and perhaps this plays
some part in confounding against their overall risk of
progression [29]. In other words, the pathophysiology of
increased GFR may differ at different ages and these dif-
ferences may themselves confer variable nephropathy risk.
In one study, the calculated odds of progression at 33.1
was double that of the next nearest (16.4) [22, 29]. There are
a number of possible explanations for this disparity of effect,
including the fact that this study was the first of its kind, and
also the smallest. In addition, progression to microalbumi-
nuria was defined as an increase in urinary albumin excretion
(determined by radioimmunoassay) by a factor of more than
3 at follow-up. When compared with all other studies, where
microalbuminuria was generally defined as 20 to 200 μg/
min, this approach may lead to overestimation of progression
to microalbuminuria based upon lower initial urinary
albumin excretion. Also, in this study, patients who
progressed had a markedly higher baseline GFR (all
>150 ml min−1 1.73 m−2) than those not progressing
compared with some of the later studies. The role of
different levels of hyperfiltration could only be assessed in
a larger study or with individual patient level data.
It has been proposed that high glomerular plasma flow
increases intracapillary pressure; there is a relative con-
striction of the efferent glomerular arteriole resulting in a
flux of plasma proteins into the mesangium [2, 35, 36].
This, in turn, leads to proliferation of mesangial cells and
matrix, a forerunner of glomerulosclerosis. One potential
cellular mechanism whereby these haemodynamic changes
may lead to this sclerotic process is the effect of stretch
induced by increased intraglomerular pressure on increas-
ing fibronectin levels in mesangial cells via p38 mitogen-
activated protein kinase, as has been demonstrated in
mouse models [37]. This has been shown to increase
podocyte hypertrophy in vitro and leads to local activation
of the angiotensin system [38, 39].
Hyperglycaemia can cause an increase in GFR, so the
role of glycaemic control and diabetes treatment is
important. Comparison of baseline glycaemic control across
the studies showed that the mean HbA1c in patients with
Fig. 3 Forest plot of studies investigating the association between baseline GFR and progression. Number of studies, n=9. aTest for heterogeneity
χ2=35.24, df=8, p<0.001; I2=77 (95% CI 57–88)%; test for overall effect Z=3.06, p=0.002
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progression was 10.5% vs 9.6% in those not progressing.
This may be a confounder in the overall calculated odds of
progression. Reported baseline blood pressure was also
higher, when available, in the progressing patients (123/77
vs 118/73 mmHg). An adjusted OR would be required to
correct for the potential confounding factors of glycaemic
control, blood pressure and diabetes duration, but in order
to achieve this, individual patient level data would be
necessary. However, in view of the age of some of the
studies involved, the original data are unlikely to be
available.
The progression to overt nephropathy as an endpoint was
also assessed. However, three of the studies were not
specifically designed or of long enough duration to look for
proteinuria [29-31] and a further study did not discriminate
between incipient and overt nephropathy [24], leaving very
small numbers for analysis.
Hyperfiltration has been associated with a greater rate of
decline in GFR [40]. Additionally, there is a normal
physiological decline in GFR associated with ageing. Most
of the individual studies assessed here were not adjusted for
age-related decline as a factor in GFR prediction or for the
effects of hyperfiltration on promoting a more rapid decline
in GFR rather than nephropathy as such, so we were unable
to analyse these effects in the identified studies [41–43].
In conclusion, in the identified studies, individuals with
type 1 diabetes who had glomerular hyperfiltration or elevat-
ed GFR subsequently had an increased risk of developing
diabetic nephropathy. However, additional studies using
patient level data are required to examine whether this
increased risk would persist after adjustment for the
confounding effects of glycaemic control, diabetes duration
and blood pressure. Confirmation of hyperfiltration as a risk
marker might enable future studies to assess how early GFR
reduction using agents that block the renin–angiotensin–
aldosterone system impacts on the development of incipient
nephropathy. Ongoing studies are evaluating these drugs, but
they are not stratifying treatment based upon baseline GFR
[44, 45].
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